Drug donanemab seen as turning point in dementia fight

The antibody treatment donanemab slows clinical decline by around a third, a large trial confirms.

BBC News

It delays dementia by 4-7 months, and also causes bleeding and swelling in the brain which killed 3 out of 1,700 participants in the study.

It’s better than nothing I guess but it’s not a particularly good treatment.